Nature Reviews Clinical Oncology – Paediatric acute myeloid leukaemia (AML) highlights the challenges of drug development for rare diseases, in which limited patient numbers and substantial…
CARGO Therapeutics announced that it will discontinue the phase 2 FIRCE-1 trial evaluating firi-cel in relapsed/refractory large B-cell lymphoma.
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented…
Immunotherapy stands as one of the most transformative breakthroughs in modern cancer treatment. These innovative therapies target signaling pathways used by cancer cells to induce…
OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.
This randomized clinical trial investigates whether adding immune therapy to adjuvant chemotherapy for triple-negative breast cancer reduces recurrent disease.
The ASTCT Translational Science Training Course is a program for young researchers and scientists involved in bench and translational science in the hematopoietic stem cell…
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients with metastatic renal cell carcinoma.
Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.
